Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

593 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
Herzog TJ, Hays JL, Barlin JN, Buscema J, Cloven NG, Kong LR, Tyagi NK, Lanneau GS, Long BJ, Marsh RL, Seward SM, Starks DC, Welch S, Moore KN, Konstantinopoulos PA, Gilbert L, Monk BJ, O'Malley DM, Chen X, Dalal R, Coleman RL, Sehouli J. Herzog TJ, et al. Among authors: coleman rl. Future Oncol. 2023 Jul;19(23):1577-1591. doi: 10.2217/fon-2023-0246. Epub 2023 Jun 19. Future Oncol. 2023. PMID: 37334673
Tisotumab vedotin in recurrent or metastatic cervical cancer.
Bogani G, Coleman RL, Vergote I, Raspagliesi F, Lorusso D, Monk BJ. Bogani G, et al. Among authors: coleman rl. Curr Probl Cancer. 2023 Jun;47(3):100952. doi: 10.1016/j.currproblcancer.2023.100952. Epub 2023 Feb 10. Curr Probl Cancer. 2023. PMID: 36842202 Review.
Selinexor in patients with advanced and recurrent endometrial cancer.
Bogani G, Monk BJ, Coleman RL, Vergote I, Oakin A, Ray-Coquard I, Mariani A, Scambia G, Raspagliesi F, Bolognese B. Bogani G, et al. Among authors: coleman rl. Curr Probl Cancer. 2023 Dec;47(6):100963. doi: 10.1016/j.currproblcancer.2023.100963. Epub 2023 May 30. Curr Probl Cancer. 2023. PMID: 37271639 Review.
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM; TACT Trial Management Group; TACT Trialists. Ellis P, et al. Lancet. 2009 May 16;373(9676):1681-92. doi: 10.1016/S0140-6736(09)60740-6. Lancet. 2009. PMID: 19447249 Free PMC article. Clinical Trial.
Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm.
Goulden S, Shen Q, Coleman RL, Mathews C, Hunger M, Pahwa A, Schade R. Goulden S, et al. Among authors: coleman rl. J Health Econ Outcomes Res. 2023 Sep 8;10(2):53-61. doi: 10.36469/001c.77484. eCollection 2023. J Health Econ Outcomes Res. 2023. PMID: 37701519 Free PMC article.
Exploring global barriers to optimal ovarian cancer care: thematic analysis.
Sfeir S, Allen L, Algera MD, Morton R, Farrell R, Brennan D, Driel WJV, Rijken MJ, Eiken M, Sundar SS, Coleman RL; collaborators of the Global Equality in Ovarian Cancer Care project group. Sfeir S, et al. Among authors: coleman rl. Int J Gynecol Cancer. 2024 May 30:ijgc-2024-005449. doi: 10.1136/ijgc-2024-005449. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 38821547
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Pitiyarachchi O, Ansell PJ, Coleman RL, Dinh MH, Holman L, Leath CA 3rd, Werner T, DiSilvestro P, Morgan M, Tew W, Lee C, Cunningham M, Newton M, Edraki B, Lim P, Barlin J, Spirtos NM, Tewari KS, Edelson M, Reid T, Carlson J, Friedlander M. Pitiyarachchi O, et al. Among authors: coleman rl. Gynecol Oncol. 2024 May 30;187:221-226. doi: 10.1016/j.ygyno.2024.05.021. Online ahead of print. Gynecol Oncol. 2024. PMID: 38821039 Free article.
LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.
Ramirez PT, Robledo KP, Frumovitz M, Pareja R, Ribeiro R, Lopez A, Yan X, Isla D, Moretti R, Bernardini MQ, Gebski V, Asher R, Behan V, Coleman RL, Obermair A. Ramirez PT, et al. Among authors: coleman rl. J Clin Oncol. 2024 May 29:JCO2302335. doi: 10.1200/JCO.23.02335. Online ahead of print. J Clin Oncol. 2024. PMID: 38810208
593 results